Study of Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis Clinical Trial

— SLAMEM  

Official title:

Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis : Neuropsychological, Imaging and Neuropathological Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01530438
• Other study ID #: 08-067
• Status: Recruiting
• Phase: N/A
• First received: February 22, 2010
• Last updated: April 8, 2014
• Start date: April 2009
• Est. completion date: May 2015

Study information

• Verified date: March 2014
• Source: University Hospital, Caen
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that involves not only motor structures, as was previously thought, but also brain areas dealing with cognition as well as parts of the limbic system. Clinical, imaging and pathological evidence suggests that ALS and fronto-temporal dementia (FTD) have several features in common, and that these two diseases could be the two ends of a pathological continuum.

Description:

Objectives : the investigators aim to study the clinical profile and magnitude of cognitive disturbances, measure brain metabolism and assess cerebral atrophy in patients with ALS. The relationships between cognitive, metabolic and anatomical data will be determined by the correlation method. In addition, pathological studies will be carried out in deceased patients having given their consent in advance, in order to quantify the neuronal loss and UBIs.

Methods : the investigators plan to recruit 60 patients with ALS, 10 patients with ALS/FTD (the diagnosis of dementia will rest on clinical data and formal neuropsychological testing) and 20 normal control subjects. The ALS patients will be divided into 2 subsets on the basis of a preliminary neuropsychological work-up, according to the presence or absence of "subclinical cognitive impairment" as defined by abnormal scoring on tests not meeting the criteria for dementia. In a second testing session carried out at the same time, a comprehensive assessment of memory, behaviour and emotional changes will be done. All subjects will then undergo morphological magnetic resonance imaging (MRI), resting-state functional MRI and 18-fluorodeoxyglucose positron emission tomography (18FDG-PET). Whenever possible, a second testing session will be carried out 9 to 12 months later in order to quantify the cognitive deterioration, if any, and to find early predictors of the evolution towards dementia. In deceased patients, the location and extent of neuronal loss will be determined, as well as the location and number of UBIs.

Results and clinical relevance : this study is intended to improve our knowledge of the clinical phenotype of ALS, and particularly to learn more about the extent of cognitive, behavioural and emotional changes in this disease. This could in turn shed some further light on the relationships between ALS and FTD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: May 2015
• Est. primary completion date: December 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• All participants :

• study level > 7 years

• mother tongue : french

• signature of the informed consent of the protocol in accord with the Comité de Protection des Personnes

• medical, neurological, neuroradiological and neuropsychological approfondis in accord with the specific inclusion and non inclusion criteria spécifiques at each population

• Patients ALS :

• 18 to 80 years old

• Diagnostic defined or probable in according to the reviewed criteria of El Escorial.

• Patients ALS / FTD :

• 18 to 8O years old

• Diagnostic defined or probable in according to El Escorial reviewed criteria and diagnostic of frontal-temporal dementia in according to Lund et Manchester criteria.

• Control Subjects :

• 45 to 75 years old

• DRS = 130

• BECK < 8

Exclusion Criteria:

• All particpants :

• Major past history (chronic pulmonary disease, cardiac disease, metabolic, haematological, endocrinological or severe immunological, cancer) ;

• Chronic use of alcohol or drugs ;

• IRM contraindications

Protected adults, and persons non affiliated to social protection system won't be able to participate at this study. The inclusion of the participant in another biomedical research protocol(during the study or into 12 months before the inclusion) is too a non inclusion criterion.

• Patients SLA and patients SLA / FTD

• Severe bulbar disorders

• Severe restrictive respiratory insufficiency (VC<50%) with orthopny

• Communication disorders with motor origin (non assessable tests)

• Control Subjects :

• Pregnant or nursing women

• Unability to submit at the study medical follow-up for geographic or psychiatric reasons(previous or ongoing).

• DRS score < 130

• Depressive syndrome (BECK) = 8

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Other:
• MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research
At T0 and T9 or 12 monts, are performed : Imaging : fMRI at rest and anatomical MRI Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ...

Locations

Country	Name	City	State
France	University Hospital Center	Caen
France	University Hospital Center	Rouen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Caen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cognitive, behavioural and emotional changes assesed with Neuropsychological tests.		Between 9 and 12 mth	No
Secondary	brain imaging (anatomical MRI, functional MRI, PET using 18FDG)		Between 9 and 12 mth	No